Phase 1 AVA6000 Clinical Trial Results were showcased at the AACR Annual Meeting on April 9, 2024

Avacta Group plc announced that updated results from their Phase 1 clinical trial of the peptide drug conjugate AVA6000 were presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego from April 5-10, 2024. The presentation, titled "A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors," was part of the Phase 1 Clinical Trials 2 Poster Session on April 9. The first author of the presentation was Dr. Udai Banerji from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

AVA6000, Avacta Therapeutics’ leading oncology program, is designed as a peptide drug conjugate combining doxorubicin with a peptide moiety, which is activated by FAP present in the tumor microenvironment. This innovative approach aims to deliver doxorubicin specifically to tumor cells, reducing systemic effects and enhancing efficacy.

Avacta Group, based in the UK, focuses on developing targeted cancer treatments and powerful diagnostics. The company operates through two main divisions: an oncology biotech division and a diagnostics division. The oncology division utilizes proprietary platforms like Affimer® and pre|CISION™ to create novel cancer therapies, while the diagnostics division leverages these platforms to enhance testing capabilities.

The pre|CISION™ platform targets chemotherapy specifically to tumor tissues by using FAP, an enzyme overexpressed in solid tumors, to activate the drug only within the tumor, minimizing systemic exposure. AVA6000 has shown significant safety improvements and early clinical activity in Phase 1 trials compared to standard doxorubicin.

Overall, Avacta aims to enhance healthcare outcomes through innovative cancer treatments and broadened diagnostic access, driving long-term shareholder value and patient benefits.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!